Skip to main content
DAE HWA PHARM CO., LTD logo

DAE HWA PHARM CO., LTD — Investor Relations & Filings

Ticker · 067080 ISIN · KR7067080002 KO Manufacturing
Open in API
Filings indexed 444 across all filing types
Latest filing 2025-09-18 Director's Dealing
Country KR South Korea
Listing KO 067080

About DAE HWA PHARM CO., LTD

http://www.dhpharm.co.kr

DAE HWA PHARM CO., LTD. is a pharmaceutical company focused on the research, development, and manufacturing of finished drug products. The company's core competency lies in its advanced Drug Delivery System (DDS) technologies, particularly its proprietary lipid-based self-emulsifying platform, DHLASED. This technology enabled the development of Liporaxel®, the world's first approved oral formulation of the anticancer agent paclitaxel. The company's portfolio also includes analgesics and anti-inflammatory drugs, such as the LOXONA trans-dermal patch, as well as aesthetic products like hyaluronic acid fillers and consumer health solutions.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details share transactions (purchases) made by a director (Kim Eun Seok) of the company (Dae Hwa Pharmaceutical). This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2025-09-18 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the shareholding status of a major shareholder and their special related parties, including changes in collateral agreements. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-08-20 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for Daehwa Pharmaceutical Co., Ltd. for the period ending June 30, 2025. It contains comprehensive financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-11 Korean
현금ㆍ현물배당결정 (분기배당)
Notice of Dividend Amount Classification · 1% confidence The document is a formal announcement from Daehwa Pharmaceutical regarding a decision to pay a cash dividend. It specifies the dividend amount per share, the total dividend amount, the record date, and the payment date. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2025-08-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of a specific individual (Kim Woon Jang, an executive at Daehwa Pharmaceutical) due to '장내매도' (on-market sale). This is a standard regulatory filing for insider trading/director dealings in the Korean market, which maps to the 'DIRS' category.
2025-08-05 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status of a major shareholder (Ko Jun-jin) and special related parties in Daewha Pharmaceutical Co., Ltd. It specifically reports changes in collateral contracts (stock-backed loans) for special related parties. This type of filing is classified as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-07-22 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.